XML 214 R157.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details) | 1 Months Ended | 3 Months Ended
--- | --- | ---
Jun. 30, 2018 Patents | Feb. 28, 2018 Patents | Jan. 31, 2018 Patents | Dec. 31, 2017 Patents | Oct. 31, 2017 Patents | Sep. 30, 2017 Patents | Jul. 31, 2017 Patents | Mar. 31, 2017 Patents | Feb. 28, 2017 Patents | Aug. 31, 2016 Patents | Jul. 31, 2016 Patents | Jan. 31, 2016 Patents | Jun. 30, 2015 Patents | Apr. 30, 2017 Defendant Patents
Patent Infringement [Member] | Judicial Ruling [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
Bosulif [Member] | Wyeth Versus Sun [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  | 2 |  |  |  |  |  |  |  |
Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  |  |  |  |  |  |  |  |  |  |  | 4 |
Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon |  |  | 1 |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  | 3 |  |  |  |  |  |  |  |  |  |  |
Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  |  |  |  |  |  |  |  | 4 |  |  |  |
Precedex Premix [Member] | Hospira Versus Gland [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  | 4 |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  |  | 6 |  |  |  |  |  |  |  |  |  |
Precedex Premix [Member] | Hospira Versus Hengrui [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  | 4 |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  |  | 6 |  |  |  |  |  |  |  |  |  |
Precedex Premix [Member] | Hospira Versus Baxter [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  | 4 |  |  |  |  |  |  |  |  |  |  |  |
Number of patents due to expire in 2019 |  | 1 |  |  |  |  |  |  |  |  |  |  |  |
Number of patents due to expire in 2032 |  | 3 |  |  |  |  |  |  |  |  |  |  |  |
Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  |  | 3 |  |  |  |  |
Xeljanz [Member] | Pfizer Versus Zydus [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  | 3 |  |  |  |  |  |
Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  | 4 |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon due to expire in December 2020 |  |  |  |  | 3 |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon due to expire in December 2025 |  |  |  |  | 1 |  |  |  |  |  |  |  |  |
Toviaz [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Judicial Ruling [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents found not infringed upon |  |  |  |  |  |  | 5 |  |  |  |  |  |  |
Toviaz [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  |  | 5 | 5 |  |
Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories and Accord Healthcare Inc. [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents infringed upon |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of patents allegedly infringed upon |  |  |  |  |  |  |  |  |  |  |  |  |  | 3
Number of defendants | Defendant |  |  |  |  |  |  |  |  |  |  |  |  |  | 25

X
- Definition Gain Contingency, Number of Defendants + References No definition available. + Details
Name: | pfe_GainContingencyNumberofDefendants
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Found Not Infringed upon, Number Due To Expire In 2019 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsFoundNotInfringeduponNumberDueToExpireIn2019
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain Contingency, Patents Found Not Infringed upon, Number Due To Expire In 2032 + References No definition available. + Details
Name: | pfe_GainContingencyPatentsFoundNotInfringeduponNumberDueToExpireIn2032
Namespace Prefix: | pfe_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_GainContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity has allegedly infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity was found to have infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of entity's patents that another entity was found not to have infringed. + References No definition available. + Details
Name: | us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_WyethVersusSunMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrecedexPremixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_HospiraVersusParMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_HospiraVersusGlandMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_HospiraVersusHengruiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_HospiraVersusBaxterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |